Duisburg, 23 January 2014. With the acquisition of the majority in Celesio AG (Celesio) by the US healthcare services company McKesson Corporation (McKesson), the two companies can now look forward to outstanding prospects in a challenging but promising market. That is the view of Stephan Gemkow, CEO of Franz Haniel & Cie. GmbH (Haniel), which today sold its 76% stake in Celesio AG to McKesson.
After McKesson's public bid of 13 January 2014 to take over Celesio failed narrowly to reach the necessary minimum acceptance threshold, Haniel increased its share in Celesio and sold its whole stake of 129.3 million shares to McKesson for EUR 23.50 per share. This equals the price of the public takeover bid, which was increased at the end of the bidding period. Stephan Gemkow: "We are delighted that McKesson has succeeded in obtaining its minimum participation in Celesio through the acquisition of Haniel's increased stake as well as through further parallel acquisitions. The two companies are an excellent fit, and I wish them - and especially their employees - every commercial success."
Haniel has sold its stake in the Stuttgart-based pharmaceutical wholesale and retail company after more than 40 years. In this period Celesio developed from a regional German wholesale company to one of the largest pan-European pharmaceutical wholesaler and retailer. In recent years, the company has also successfully gained a foothold in South America.
Haniel will use the cash inflow to further reduce its net financial debt at holding level and to invest in strategic portfolio opportunities.